Combining dose and injection volume for good performance of a specific radiopharmaceutical for sentinel node detection

Nuclear Medicine and Biology

Volumn 39, Issue 1, 2012, Pages 145-153

  Núñez, Eutimio Gustavo Fernández ^a   de Oliveira, Erica Aparecida ^a   da Silva, Natanael Gomes ^a   de Oliveira Filho, Renato Santos ^b  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Dosage; Injected volume; Sentinel lymph node detection; Technetium 99m; Tissue specific radiopharmaceutical

Indexed keywords

CYSTEINE MANNOSE DEXTRAN TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG RETENTION; FEMALE; INJECTION; NONHUMAN; POPLITEAL NODE; RADIOACTIVITY; RAT; SENTINEL LYMPH NODE; TRANSPORT KINETICS;

ANIMALS; CYSTEINE; DEXTRANS; FEMALE; LYMPH NODES; MANNOSE; ORGANOTECHNETIUM COMPOUNDS; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; SENTINEL LYMPH NODE BIOPSY; TISSUE DISTRIBUTION;

EID: 84855312837     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2011.07.004     Document Type: Article

References (34)

1. Alkureishi L.W.T., Burak Z., Alvarez J.A., Ballinger J., Bilde A., Britten A.J., et al. Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging 2009, 36:1915-1936.
2. Brenot-Rossi I., Rossi D., Esterni B., Brunelle S., Chuto G., Bastide C. Radioguided sentinel lymph node dissection in patients with localised prostate carcinoma: influence of the dose of radiolabelled colloid to avoid failure of the procedure. Eur J Nucl Med Mol Imaging 2008, 35:32-38.
3. Adib T., Barton D.P.J. The sentinel lymph node: relevance in gynaecological cancers. Eur J Surg Oncol 2006, 32:866-874.
4. Yanagita S., Natsugoe S., Uenosono Y., Arigami T., Arima H., Kozono T., et al. Detection of micrometastases in sentinel node navigation surgery for gastric cancer. Surg Oncol 2008, 17(3):203-210.
5. Schauer A.J., Becker W., Reiser M., Possinger K. The sentinel lymph node concept 2005, Springer-Verlag, Würzburg, Germany.
6. Fehr M.K., Hornung R., Varga Z., Burger D., Hess T., Haller U., et al. Axillary staging using positron emission tomography in breast cancer patients qualifying for sentinel lymph node biopsy. Breast J 2004, 10(2):89-93.
7. Strickland A.H., Beechey-Newman N., Steer C.B., Harper P.G. Sentinel node biopsy: an in depth appraisal. Crit Rev Oncol Hematol 2002, 44:45-70.
8. Belhocine T., Driedger A. 18F-fluorodeoxyglucose positron emission tomography in oncology: advantages and limitations. Cancer Imaging: Instrumentation and Applications 2008, 193-200. Elsevier Academic Press, California. M.A. Hayat (Ed.).
9. Coughlin A., Resto V.A. Oral cavity squamous cell carcinoma and the clinically N0 neck: the past, present, and future of sentinel lymph node biopsy. Curr Oncol Rep 2010, 12:129-135.
10. Ellner S.J., Méndez J., Vera D.R., Hoh C.K., Ashburn W.L., Wallace A.M. Sentinel lymph node mapping of the colon and stomach using Lymphoseek in a pig model. Ann Surg Oncol 2004, 11:674-681.
11. Styblo T., Aarsvold J.N., Grant S.F., Cohen C., Larsen T., Waldrop S., et al. Sentinel lymph nodes: optimizing success. Semin Roentgenol 2001, 36:261-269.
12. Aarsvold J.N., Alazraki N.P. Update on detection of sentinel lymph nodes in patients with breast cancer. Semin Nucl Med 2005, 35:116-128.
13. Tanis P.J., Nieweg O.E., Valdés Olmos R.A., Kroon B.B.R. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg 2001, 192:399-409.
14. Zeevaart J.R., Olsen S. Recent trends in the concept of specific activity: Impacton radiochemical and radiopharmaceutical producers. Appl Radia. Isotopes 2006, 64:812-814.
15. Obled C., Papet I., Breuillé D. Sulfur-containing amino acids and glutathione in diseases. Metabolic and therapeutic aspects of amino acids in clinical nutrition 2004, 667-688. CRC Press, Florida. L.A. Cynober (Ed.).
16. Brody T. Nutritional Biochemistry 1999, Academic Press, California. 2nd ed.
17. 99mTc-DTPA-Mannosyl-Dextran. J Nucl Med 2001, 42:951-959.
18. Patel S., Gibson R. In vivo site-directed radiotracers: a mini-review. Nucl Med Biol 2008, 35:805-815.
19. Vallabhajosula S., Owunwanne A. Pathophysiology and mechanisms of radiopharmaceutical localization. The pathophysiologic basis of nuclear medicine 2006, 29-49. Springer, Germany. A.H. Elgazzar (Ed.).
20. Schöder H., Glass E.C., Pecking A.P., Harness J.K., Wallace A.M., Hirnle P., et al. Molecular targeting of the lymphovascular system for imaging and therapy. Cancer Metastasis Rev 2006, 25:185-201.
21. Knapp D.W., Adams L.G., DeGrand A.M., Niles J.D., Ramos-Vara J.A., Weil A.B., et al. Sentinel lymph node mapping of invasive urinary bladder cancer in animal models using invisible light. Eur Urol 2007, 52:1700-1709.
22. van Esser S., Hobbelink M., Van Isselt J.W., Mali W.P.Th.M., Borel Rinkes I.H.M., van Hillegersberg R. Comparison of a 1-day and a 2-day protocol for lymphatic mapping and sentinel lymph node biopsy in patients with nonpalpable breast cancer. Eur J Nucl Med Mol Imaging 2009, 36:1383-1387.
23. 99mTc]MAG3-mannosyl-dextran: a receptor-binding radiopharmaceutical for sentinel node detection. Nucl Med Biol 2001, 28:493-498.
24. Fernández Núñez E.G., Teodoro R., Wiecek D.P., da Silva N.G., Martinelli J.R., de Oliveira Filho R.S. Size and specificity of radiopharmaceuticals for sentinel lymph node detection. Acta Radiol 2011, 52:774-778.
25. Swartz M.A. The physiology of the lymphatic system. Adv Drug Deliv Rev 2001, 50:3-20.
26. Fernández Núñez E.G., Faintuch B.L., Teodoro R., Wiecek D.P., Martinelli J.R., da Silva N.G., et al. Influence of colloid particle profile on sentinel lymph node uptake. Nucl Med Biol 2009, 36:741-747.
27. Jeong J.M., Hong M.K., Kim Y.J., Lee J., Kang J.H., Lee D.S., et al. Development of 99mTc-neomannosyl human serum albumin (99mTc-MSA) as a novel receptor binding agent for sentinel lymph node imaging. Nucl Med Commun 2004, 25:1211-1217.
28. Ellner S.J., Hoh C.K., Vera D.R., Darrah D.D., Schulteis G., Wallace A.M. Dose-dependent biodistribution of [(99m)Tc]DTPA-mannosyl-dextran for breast cancer sentinel lymph node mapping. Nucl Med Biol 2003, 30(8):805-810.
29. Wawroschek F., Wengenmair H., Senekowitsch-Schmidtke R., Hamm M., Henke J., Schönberger T., et al. Prostate lymphoscintigraphy for sentinel lymph node identification in canines: reproducibility, uptake, and biokinetics depending on different injection strategies. Urol Res 2003, 31:152-158.
30. Vermeeren L., Muller S.H., Meinhardt W., Valdés Olmos R.A. Optimizing the colloid particle concentration for improved preoperative and intraoperative image-guided detection of sentinel nodes in prostate cancer. Eur J Nucl Med Mol Imaging 2010, 37:1328-1334.
31. Bigott-Hennkens H.M., Dannoon S., Lewis M.R., Jurisson S.S. In vitro receptor binding assays: general methods and considerations. Q J Nucl Med Mol Imaging 2008, 52:1-9.
32. Servais E.L., Colovos C., Bograd A.J., White J., Sadelain M., Adusumilli P.S. Animal models and molecular imaging tools to investigate lymph node metastases. J Mol Med 2011, 89:753-769.
33. Praaning-Van Dalen D.P., DeLeeuw A.M., Brouwer A., Knook D.L. Rat liver endothelial cells have a greater capacity than Kupffer cells to endocytose yV-acetylglucosamineand mannose-terminated glycoproteins. Hepatology 1987, 7:672-679.
34. Decuzzi P., Ferraric M. The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials 2007, 28:2915-2922.